LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
View the Zacks #1 Rank List
Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings
Immix Biopharma will participate in the Morgan Stanley Global Healthcare Conference, hosting investor meetings on relapsed/refractory AL Amyloidosis.
Quiver AI Summary
Immix Biopharma, Inc. has announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference taking place from September 14-16, 2026, in New York, where the company will host meetings with institutional investors. ImmixBio specializes in treating relapsed/refractory AL Amyloidosis, a serious disease characterized by the production of toxic light chains by the immune system, which can lead to organ failure. Their leading treatment, NXC-201, is a CAR-T cell therapy designed to target and eliminate these harmful light chains. It is currently being studied in a significant multi-center trial and has received various designations from the FDA, including Breakthrough Therapy and Orphan Drug status. Investors interested in meetings are encouraged to reach out through their Morgan Stanley representative. Further information will be available on the Immix website post-conference.
Potential Positives
Potential Negatives
FAQ
What is the Morgan Stanley Global Healthcare Conference?
The Morgan Stanley Global Healthcare Conference is an annual event where healthcare companies present their innovations and meet with institutional investors.
When will Immix Biopharma participate in the conference?
Immix Biopharma will participate in the conference from September 14-16, 2026, in New York, NY.
How can investors request one-on-one meetings with Immix Bio?
Investors can contact their Morgan Stanley representative to request one-on-one meetings with Immix Biopharma during the conference.
What is NXC-201?
NXC-201 is Immix Biopharma's lead CAR-T cell therapy designed to treat relapsed/refractory AL Amyloidosis by targeting toxic light chains.
What designations has NXC-201 received from the FDA?
NXC-201 has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug Designation from the FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMX Hedge Fund Activity
We have seen 44 institutional investors add shares of $IMMX stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IMMX Price Targets
Multiple analysts have issued price targets for $IMMX recently. We have seen 7 analysts offer price targets for $IMMX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
Full Release
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact irteam@immixbio.com
Read full article here »